180 related articles for article (PubMed ID: 7647787)
1. Loss of function effect of RET mutations causing Hirschsprung disease.
Pasini B; Borrello MG; Greco A; Bongarzone I; Luo Y; Mondellini P; Alberti L; Miranda C; Arighi E; Bocciardi R
Nat Genet; 1995 May; 10(1):35-40. PubMed ID: 7647787
[TBL] [Abstract][Full Text] [Related]
2. Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease.
Pelet A; Geneste O; Edery P; Pasini A; Chappuis S; Atti T; Munnich A; Lenoir G; Lyonnet S; Billaud M
J Clin Invest; 1998 Mar; 101(6):1415-23. PubMed ID: 9502784
[TBL] [Abstract][Full Text] [Related]
3. Two distinct mutations of the RET receptor causing Hirschsprung's disease impair the binding of signalling effectors to a multifunctional docking site.
Geneste O; Bidaud C; De Vita G; Hofstra RM; Tartare-Deckert S; Buys CH; Lenoir GM; Santoro M; Billaud M
Hum Mol Genet; 1999 Oct; 8(11):1989-99. PubMed ID: 10484767
[TBL] [Abstract][Full Text] [Related]
4. Molecular heterogeneity of RET loss of function in Hirschsprung's disease.
Carlomagno F; De Vita G; Berlingieri MT; de Franciscis V; Melillo RM; Colantuoni V; Kraus MH; Di Fiore PP; Fusco A; Santoro M
EMBO J; 1996 Jun; 15(11):2717-25. PubMed ID: 8654369
[TBL] [Abstract][Full Text] [Related]
5. Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines.
Chappuis-Flament S; Pasini A; De Vita G; Ségouffin-Cariou C; Fusco A; Attié T; Lenoir GM; Santoro M; Billaud M
Oncogene; 1998 Dec; 17(22):2851-61. PubMed ID: 9879991
[TBL] [Abstract][Full Text] [Related]
6. Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung disease.
Angrist M; Bolk S; Thiel B; Puffenberger EG; Hofstra RM; Buys CH; Cass DT; Chakravarti A
Hum Mol Genet; 1995 May; 4(5):821-30. PubMed ID: 7633441
[TBL] [Abstract][Full Text] [Related]
7. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
Carlomagno F; Melillo RM; Visconti R; Salvatore G; De Vita G; Lupoli G; Yu Y; Jing S; Vecchio G; Fusco A; Santoro M
Endocrinology; 1998 Aug; 139(8):3613-9. PubMed ID: 9681515
[TBL] [Abstract][Full Text] [Related]
8. The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma.
Borrello MG; Alberti L; Arighi E; Bongarzone I; Battistini C; Bardelli A; Pasini B; Piutti C; Rizzetti MG; Mondellini P; Radice MT; Pierotti MA
Mol Cell Biol; 1996 May; 16(5):2151-63. PubMed ID: 8628282
[TBL] [Abstract][Full Text] [Related]
9. Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease.
Attié T; Pelet A; Edery P; Eng C; Mulligan LM; Amiel J; Boutrand L; Beldjord C; Nihoul-Fékété C; Munnich A
Hum Mol Genet; 1995 Aug; 4(8):1381-6. PubMed ID: 7581377
[TBL] [Abstract][Full Text] [Related]
10. RET activation by germline MEN2A and MEN2B mutations.
Borrello MG; Smith DP; Pasini B; Bongarzone I; Greco A; Lorenzo MJ; Arighi E; Miranda C; Eng C; Alberti L
Oncogene; 1995 Dec; 11(11):2419-27. PubMed ID: 8570194
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of ret dysfunction by Hirschsprung mutations affecting its extracellular domain.
Iwashita T; Murakami H; Asai N; Takahashi M
Hum Mol Genet; 1996 Oct; 5(10):1577-80. PubMed ID: 8894691
[TBL] [Abstract][Full Text] [Related]
12. Key role of Shc signaling in the transforming pathway triggered by Ret/ptc2 oncoprotein.
Mercalli E; Ghizzoni S; Arighi E; Alberti L; Sangregorio R; Radice MT; Gishizky ML; Pierotti MA; Borrello MG
Oncogene; 2001 Jun; 20(27):3475-85. PubMed ID: 11429694
[TBL] [Abstract][Full Text] [Related]
13. Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade.
Melillo RM; Santoro M; Ong SH; Billaud M; Fusco A; Hadari YR; Schlessinger J; Lax I
Mol Cell Biol; 2001 Jul; 21(13):4177-87. PubMed ID: 11390647
[TBL] [Abstract][Full Text] [Related]
14. Germline mutations in glial cell line-derived neurotrophic factor (GDNF) and RET in a Hirschsprung disease patient.
Angrist M; Bolk S; Halushka M; Lapchak PA; Chakravarti A
Nat Genet; 1996 Nov; 14(3):341-4. PubMed ID: 8896568
[TBL] [Abstract][Full Text] [Related]
15. Mutations in the extracellular domain cause RET loss of function by a dominant negative mechanism.
Cosma MP; Cardone M; Carlomagno F; Colantuoni V
Mol Cell Biol; 1998 Jun; 18(6):3321-9. PubMed ID: 9584172
[TBL] [Abstract][Full Text] [Related]
16. Specific polymorphisms in the RET proto-oncogene are over-represented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression.
Borrego S; Sáez ME; Ruiz A; Gimm O; López-Alonso M; Antiñolo G; Eng C
J Med Genet; 1999 Oct; 36(10):771-4. PubMed ID: 10528857
[TBL] [Abstract][Full Text] [Related]
17. RET and GDNF gene scanning in Hirschsprung patients using two dual denaturing gel systems.
Hofstra RM; Wu Y; Stulp RP; Elfferich P; Osinga J; Maas SM; Siderius L; Brooks AS; vd Ende JJ; Heydendael VM; Severijnen RS; Bax KM; Meijers C; Buys CH
Hum Mutat; 2000; 15(5):418-29. PubMed ID: 10790203
[TBL] [Abstract][Full Text] [Related]
18. A mutation in the RET proto-oncogene in Hirschsprung's disease affects the tyrosine kinase activity associated with multiple endocrine neoplasia type 2A and 2B.
Cosma MP; Panariello L; Quadro L; Dathan NA; Fattoruso O; Colantuoni V
Biochem J; 1996 Mar; 314 ( Pt 2)(Pt 2):397-400. PubMed ID: 8670046
[TBL] [Abstract][Full Text] [Related]
19. Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation.
Iwashita T; Asai N; Murakami H; Matsuyama M; Takahashi M
Oncogene; 1996 Feb; 12(3):481-7. PubMed ID: 8637703
[TBL] [Abstract][Full Text] [Related]
20. Investigation of germline GFR alpha-1 mutations in Hirschsprung disease.
Myers SM; Salomon R; Goessling A; Pelet A; Eng C; von Deimling A; Lyonnet S; Mulligan LM
J Med Genet; 1999 Mar; 36(3):217-20. PubMed ID: 10204848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
